BOSTON, Massachusetts, May 1 /PRNewswire/ -- Sidec announces the first Protein Tomography(TM) Award at Sidec's Executive Forum at PEGS. This Award is set up to enable research groups in the biopharmaceutical industry, who have not yet collaborated with Sidec on a Protein Tomography(TM) study, to get acquainted with Sidec's groundbreaking technology successfully used in cancer drug research.
Sidec announced today the first Protein Tomography(TM) Award. The winning project will obtain a Protein Tomography(TM) collaboration financed by Sidec. This announcement was made at Sidec's Executive Forum during the fourth Annual PEGS meeting organized by CHI.
The use of Protein Tomography(TM) to answer questions related to therapeutic antibody development was presented at Sidec's Executive Forum. Berkley Lynch, previously Principal Investigator at UCB, spoke about the use of Protein Tomography(TM) to Image the Synaptic Vesicle of protein 2A in situ and Jose R. Casas-Finet, Director, R&D and Medical Biochemistry, MedImmune showed how antibody conformations and interactions can be studied by Protein Tomography(TM). At the Forum, Wim, K. Bleeker, Director Translational Research & Pharmacology at Genmab presented the modes of action of HuMax-EGFr (zalutumumab) published in PNAS April 22nd and how this was determined together with Sidec using Protein Tomography(TM).
Finally, Kathleen Madden Williams, PhD, JD Edwards Agnell Palmer & Dodge LLP discussed the ever-narrowing tunnel that present day patent protection on antibodies has entered and whether there is a gold standard by which antibodies are distinguishable from one another thereby to enable more meaningful patent protection.
"During PEGS it became obvious that studying molecular mechanisms is
indeed a crucial step in antibody development. Even for
|SOURCE Sidec AB|
Copyright©2008 PR Newswire.
All rights reserved